Is hearing loss a common symptom of Breast Cancer? What causes it and how can it be managed?

Hearing loss is not typically a direct symptom of breast cancer itself; it more often relates to the treatments some people receive rather than the tumor. ^[1] In particular, certain chemotherapy drugs (especially platinum agents like cisplatin) are well known to damage the inner ear and cause hearing problems, while hormone therapy for breast cancer does not commonly cause hearing loss. ^{[2] [1]}

How hearing loss can happen

• Chemotherapy ototoxicity (ear toxicity): Cisplatin can injure the inner ear, leading to tinnitus (ringing), high‑frequency hearing loss, and sometimes difficulty understanding speech; this effect can occur during or after treatment and may be permanent or progressive with repeated doses. ^{[2] [3]} Hearing changes can be unilateral or bilateral and may include vestibular (balance) problems. ^{[2] [4]}

• Combined drug risks: Ototoxicity risk can worsen if platinum drugs are given with other nephrotoxic or ototoxic medicines (for example, aminoglycoside antibiotics), so careful medication review is important. ^{[5] [6]}

• Radiation effects: When radiation is delivered near the ear, it can sometimes affect hearing; in breast cancer, radiation is typically to the chest, so ear involvement is uncommon, but therapy-related ear toxicity is recognized across cancer care. ^[7]

• Less common mechanisms: Rarely, nervous system complications related to cancer (paraneoplastic syndromes) can affect sensory functions, but hearing impairment as a paraneoplastic manifestation is unusual and not a typical breast cancer presentation. ^{[8] [9]}

Bottom line: Most hearing loss in people treated for breast cancer is more likely tied to specific therapies (not the cancer itself), with platinum chemotherapies being the most established cause. ^{[1] [2]}

---

What symptoms to watch for

• Ringing or buzzing (tinnitus), especially new or worsening. ^[2]
• Trouble hearing high‑pitched sounds or understanding speech, especially in noisy places. ^{[2] [10]}
• Ear fullness, imbalance, or dizziness. ^[2]

If these develop during treatment, prompt reporting helps protect hearing and guide dose adjustments. Audiometry is generally recommended if symptoms appear. ^{[5] [6]}

---

Monitoring and prevention

• Baseline and periodic hearing tests (audiometry): If you are receiving or being considered for ototoxic drugs (like cisplatin), a baseline test and follow‑up monitoring can help detect early changes. ^{[11] [6]}

• Medication review and risk reduction: Clinicians often avoid combining cisplatin with other ototoxic or nephrotoxic agents when possible and adjust doses based on toxicity. ^{[5] [6]}

• Early symptom reporting: Let your care team know about tinnitus or hearing changes immediately; ear toxicity can be cumulative and may become irreversible, so early action matters. ^{[3] [10]}

---

Management options

• Oncology adjustments: Depending on severity, your team may consider dose reduction, treatment delay, or switching regimens to limit further ear damage. ^[6]

• Audiology care: Specialized hearing services provide diagnostic evaluation, counseling, and rehabilitation for treatment‑related hearing loss, including tinnitus strategies and balance assessments. ^[7]

• Hearing rehabilitation:

  • Hearing aids or assistive listening devices to improve communication. ^[7]
  • Tinnitus management (sound therapy, counseling) to reduce distress. ^[7]
  • Communication strategies (face-to-face speaking, quiet environments) to compensate for high‑frequency loss. ^[7]

• Safety and daily function: Balance issues may be addressed with vestibular therapy; lifestyle adjustments (avoiding loud noise exposure) can help protect remaining hearing. ^{[2] [7]}

Important note: Cisplatin‑related hearing loss is often dose‑related and may be irreversible, so prevention and early detection are key. ^{[3] [10]}

---

Where this fits within breast cancer care

• Common breast cancer treatments and ear risk: Standard breast cancer care includes surgery, radiation to the breast/chest wall, chemotherapy, targeted therapy, and hormone therapy; among these, the ear toxicity signal is strongest with platinum agents, which are not routinely used for all breast cancers but may be used in specific situations. ^{[1] [2]}

• Other frequent side effects: Fatigue, nausea, hair loss, infection risk, and neuropathy are far more typical than hearing loss with many breast cancer regimens. ^[1] If hearing changes occur, they merit prompt evaluation because they are less usual in standard breast cancer therapy. ^[1]

---

Practical tips for you

• Ask whether your regimen includes ototoxic drugs (like cisplatin). ^[2]
• Request baseline and follow‑up hearing tests if at risk or symptomatic. ^[11]
• Report tinnitus or any hearing change immediately; don’t wait for it to “settle.” ^[5]
• Protect your ears: avoid loud noise, use hearing protection, and limit nonessential ototoxic medications. ^{[5] [6]}
• Seek audiology support early: rehabilitation can improve day‑to‑day communication and quality of life. ^[7]

---

Summary

Hearing loss is not a common symptom of breast cancer itself. ^[1] It is more likely linked to certain treatments especially platinum chemotherapy such as cisplatin which can cause tinnitus and high‑frequency hearing loss that may be permanent and cumulative. ^{[2] [3]} Monitoring with audiometry, early symptom reporting, thoughtful drug selection, and audiology‑led rehabilitation are the mainstays of prevention and management. ^{[5] [11] [7]}